Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrimack Pharmaceuticals
With
Sanofi
This is a multicenter, open-label, randomized, Phase II study of preoperative MM-121 with paclitaxel in HER2-negative breast cancer. Patients will be randomized to receive paclitaxel with or without MM-121 for 12 weeks followed by 4 cycles of doxorubicin plus cyclophosphamide and subsequent surgery.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histological confirmation of ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2)
Free of metastatic disease
≥ 18 years old
Female
Had no prior treatment for any cancer
Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide
You may not be if
Have a history of severe allergic reactions to paclitaxel or other drugs formulated in Cremaphor® EL
Are pregnant or breastfeeding
Clareo Health | A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
